Bladder epicheck page title Bladder epicheck page title mobile

Detect bladder cancer recurrences with a simple, non-invasive and accurate urine test

THE NEED

Bladder cancer is the 5th most common cancer in the western world, and 70%-80% of the patients are diagnosed with non-muscle invasive disease.  There are estimated 400,000 to 800,000 active bladder cancer patients in the United States, as well as 1 to 2 million in Europe, who undergo local resection of the tumor and then have 1-4 follow-up visits each year due to the high recurrence rate of the disease. Follow-ups include cystoscopy procedures that are invasive and painful, are negative in 90% of cases, and detect only 70-80% of recurrences. Both cystoscopy and cytology are subjective, costly and highly dependent on the operator expertise. Therefore, there is a clear need for a non-invasive, robust and simple tool to follow-up non-muscle-invasive bladder cancer patients.

 

 

bladder illustration

OUR SOLUTION

Bladder EpiCheck provides patients and clinicians with a simple, objective urine test to detect recurrence of bladder tumors. The test analyzes subtle disease-specific changes in DNA methylation markers, allowing for the detection of 92%1 of the high-risk (non Ta-LG) cancers. High risk cancers2 are important to catch as they are aggressive and most likely to progress to invasive cancer if not treated immediately. Bladder EpiCheck demonstrated Negative Predictive Value (NPV) of 99%1 for high-risk cancer, meaning that when receiving a negative Bladder EpiCheck result, there is 99%1 chance that no high-risk cancer is present. Bladder EpiCheck is an objective molecular test meaning that it does not rely on human interpretation. The result is a clear positive/negative for presence of bladder cancer, with an additional numerical results between 0-100. Bladder EpiCheck can be used in a surveillance regimen to increase confidence in detection of recurrence and/or to reduce amount of cystoscopies.

 

 

 

nucleixtube name change

BEST IN CLASS PERFORMANCE-Bladder EpiCheck is CE marked

Results of a European multi-center study, performed in leading urology centers in the Netherlands, Germany, Spain and Israel, compared Bladder EpiCheck to cystoscopy, cytology and pathology for the detection of Non-muscle-invasive bladder cancer recurrence.

 
  • 99 %

    NPV

    (excluding Ta-LG)

  • 92 %

    SENSITIVITY

    (excluding Ta-LG)

  • 88 %

    SPECIFICITY

     

BEST IN CLASS PERFORMANCE-Bladder EpiCheck is CE marked

Results of a European multi-center study, performed in leading urology centers in the Netherlands, Germany, Spain and Israel, compared Bladder EpiCheck to cystoscopy, cytology and pathology for the detection of Non-muscle-invasive bladder cancer recurrence.

 

SOCIAL MEDIA

Subscribe to one of our social media channels

close

Subscription Confirmation Required

Go to your email inbox

Go to your email inbox

Go to the inbox of the email
address you just used to sign up.

Open the confirmation email

Open the confirmation email

Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.

Click the confirmation link

Click the confirmation link

Click on the link inside the
email and you’re good to go.

GOT IT !